Aug 2026
A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.
Overall, NIID-002 fulfills the key requirements for the pandemic preparedness of CVV, combining reduced pathogenicity, broad antigenic reactivity, and adequate production efficiency, which underscores the continued need for surveillance and refinement of influenza vaccine strategies to address evolving viral threats.
Yasushi Suzuki, Tomoko Arita, Masayuki Shirakura et al.
· Vaccine · 0 citations